Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVRx, Inc. (NASDAQ: CVRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular diseases, and its filings offer detailed insight into the Barostim platform, financial performance and risk profile.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue trends, gross margin, operating expenses, cash and cash equivalents, long-term debt and stockholders’ equity, as well as narrative discussions of the business and risk factors. These filings also describe CVRx’s focus on Barostim for heart failure, regulatory approvals such as FDA approval and CE Mark, and the importance of reimbursement and coding decisions to the company’s operations.
Current reports on Form 8-K document material events, including the release of quarterly financial results and key corporate developments. For example, CVRx has filed 8-Ks to furnish earnings press releases and to disclose the appointment of a Chief Operating Officer, along with details about compensation arrangements. Such filings help investors track significant changes in management, financing and operating plans.
Through this page, users can also access information related to CVRx’s capital structure, including term loan agreements secured by substantially all of the company’s assets, as described in its public communications. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as revenue drivers, Barostim-related updates, reimbursement discussions and key risk disclosures. Real-time updates from EDGAR, along with AI explanations of 10-Ks, 10-Qs and 8-Ks, allow investors to follow how CVRx’s regulatory reporting reflects the evolution of its heart failure therapy business.
Morrison Gregory reported acquisition or exercise transactions in this Form 4 filing.
CVRx, Inc. reported that Chief Human Resources Officer Gregory Morrison received equity awards on March 2, 2026. He was granted 154,500 stock options and 34,000 shares of common stock at no cost. The common stock represents restricted stock units vesting 25% annually, while the options vest 25% on March 2, 2027 and monthly thereafter.
CVRx, Inc. filed an initial statement of beneficial ownership for executive Gregory Morrison, who serves as Chief Human Resources Officer. This Form 3 establishes his status as an insider of the company and provides the baseline disclosure of his equity holdings for future reporting under securities rules.
CVRx, Inc. president and CEO Kevin Hykes reported both an equity award and a small tax-related sale. He received a grant of 238,000 stock options and 159,000 restricted shares, which vest over several years. To cover tax withholding from these awards, he sold 7,763 common shares at a weighted average price of $7.9027 per share in mandated sell-to-cover transactions. After these trades, he directly owned 284,237 common shares.
CVRx, Inc. Chief Marketing & Strategy Officer Paul Verrastro reported a mix of equity grants and a small sale. On February 27, 2026, he acquired 45,000 shares of common stock as restricted stock units and a 67,000-share stock option grant, both at no cost.
The restricted stock units vest 25% on each annual anniversary of the grant date, while the option vests 25% on February 27, 2027 and then monthly in equal installments. On March 2, 2026, he sold 1,284 shares of common stock at a weighted average price of
CVRx, Inc. chief financial officer Jared Oasheim reported a mix of equity grants and a small mandated share sale. He received a grant of 91,000 stock options at an exercise price of
CVRx, Inc. Chief Revenue Officer John Robert Allen reported a mix of stock sales and awards. He sold 3,964 shares of common stock in an open-market transaction at a weighted average price of
CVRx, Inc. chief operating officer Brent Binkowski reported equity awards on February 27, 2026. He received 23,000 stock options with an exercise price of $0.00 per share and a separate grant of 15,000 shares of common stock, both classified as awards rather than open-market purchases.
The 15,000-share common stock grant consists of restricted stock units that vest in four equal annual installments of 25% on each anniversary of the grant date. The 23,000-stock-option award vests as to 25% of the shares on February 27, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. After these transactions, Binkowski directly owned 31,600 shares of common stock, according to the filing.
CVRx, Inc. approved a new performance stock unit (PSU) program for its executive officers tied to a cumulative revenue goal over the fiscal 2026–2027 period. This incremental award is in addition to their regular annual equity grants.
For named executive officers, the grant date value of these PSUs equals three-fourths of their 2026 annual long-term incentive value. Payouts range from 50% of target at threshold performance to 200% at maximum. Any earned PSUs vest 50% after the revenue goal is certified and 50% on December 31, 2028, generally requiring continued employment and including provisions for accelerated or continued vesting upon death, disability, certain terminations, or qualifying change in control events.
CVRx director-associated entity reports open-market share purchase. Treo Ventures I, L.P., an entity for which director Mudit K. Jain is the general partner, bought 46,800 shares of CVRx common stock on February 20, 2026 at a weighted average price of $6.3588 per share, with individual prices ranging from $5.8500 to $6.3868. Jain also directly holds 5,650 common shares after these transactions.
CVRx, Inc. director Mudit K. Jain reported an open-market purchase of 600 shares of common stock at a weighted average price of $4.6417 per share on February 18, 2026. Following this transaction, he directly holds 5,650 common shares.
In addition, 933,383 common shares are held indirectly through Treo Ventures I, L.P., where Jain is the general partner and shares voting and dispositive power. He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.